National Graphite Corp. (NGRC)

0.0560 -0.0120 (-17.65%) At close: 03:46PM EDT

National Graphite Corp.

Linienstrasse 75
Duesseldorf 40237
Germany
49 172 6544175

Sector(s): Financial Services
Industry: Shell Companies
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mrs. Ulrike Dickmann	Chief Executive Officer, President, Chief Financial Officer and Director	N/A	N/A	1953
Ms. Verena Becchio	Secretary & Director	N/A	N/A	1942

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.

Corporate governance

National Graphite Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.